HIV-1 new target small molecule drug candidates found

hiv drugs were the most effective means of fighting AIDS before the success of AIDS vaccine research and development. According to the Kunming Institute of Zoology of the Chinese Academy of Sciences, the research team has recently found a candidate for a new HIV-1 target small molecule drug, the results of which have been published in
research.
The team, in collaboration with Sun Handung, a member of the Kunming Plant Research Institute of the Chinese Academy of Sciences, systematically screened and studied natural small molecular compounds from sources such as serum flavonoids, narrow-leaf flavours, and small flower flavonoids, and found that the ligand compound SM-10 from the source of small flower mists had better anti-HIV activity. Through further research, they found that synthetic intermediate SJP-L-5 activity was much better than SM-10.
, the research team, in collaboration with Xiao Wealy of the Key Laboratory of Natural Resources Drug Chemistry of Yunnan University, conducted an in-depth study on the mechanism of SJP-L-5 anti-HIV action and found that SJP-L-5 can effectively inhibit the late stage of reverse transcription. They used a high-sensitivity probe for southern ink point gene hybridization experiments to confirm that SJP-L-5 inhibited the synthesis of positive-chain virus DNA, but also destroyed the structure of the virus cPPT folding wing, resulting in downstream positive-chain DNA 5 fragmented replication products. Since cPPT folding is an important part of the virus's nucleation, its absence prevents the virus DNA from entering the nucleus. Genotype resistance and esotypic resistance experiments have shown that two genes are important places for SJP-L-5 to bind to reverse enzymes and are the structural basis for the formation of new mechanisms for this compound. This study is the first to confirm that cPPT folding wing is a new anti-HIV target, SJP-L-5 is a new small molecule drug candidate acting on this new target, the study provides a new way of thinking for the development of new target anti-HIV drugs. (Source: Science and Technology Daily Zhao Hanbin)